inclusion criteria: - the subjects ≥ 18 years old who has completed one dose of recombinant ad5 vectored covid-19 vaccine. - the subjects can provide with informed consent and sign informed consent form (icf). - the subjects are able to and willing to comply with the requirements of the clinical trial program and can complete the 6-month follow-up of the study. - axillary temperature ≤ 37.0 ℃ - individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator and meet the requirements of these products immunization.

inclusion criteria: - the subjects ≥ 18 years old who has completed one dose of recombinant ad5 vectored covid-19 vaccine. - the subjects can provide with informed consent and sign informed consent form (icf). - the subjects are able to and willing to comply with the requirements of the clinical trial program and can complete the 6-month follow-up of the study. - axillary temperature ≤ 37.0 ℃ - individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator and meet the requirements of these products immunization.

inclusion criteria: - subjects over 18 years old who has completed one dose of recombinant ad5 vectored covid-19 vaccine. - the subject can provide with informed consent and sign informed consent form (icf). - the subjects were able to and willing to comply with the requirements of the clinical trial program and could complete the 6-month follow-up of the study. - axillary temperature ≤ 37.0 ℃ - individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator and meet the requirements of these products immunization.

inclusion criteria: - subjects over 18 years old who has completed one dose of recombinant ad5 vectored covid-19 vaccine. - the subject can provide with informed consent and sign informed consent form (icf). - the subjects were able to and willing to comply with the requirements of the clinical trial program and could complete the 6-month follow-up of the study. - axillary temperature ≤ 37.0 ℃ - individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator and meet the requirements of these products immunization.